About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 4NCT03823950

Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients

Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection....

Lead sponsor: University of Mississippi Medical Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Anderson B Collier, MD

CONTACT

601-984-5221 acollier@umc.edu

Sponsors

Lead Sponsor

University of Mississippi Medical Center

Age

0 - 21 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. are between the ages of birth and 21 years old
•2. is diagnosed with an oncologic disease
•3. is being treated at UMMC Children's Cancer Clinic
•4. will receive G-CSF as part of their standard or experimental oncology treatment protocol between January 1, 2019 and December 31, 2019. Oncology treatment protocols are typically derived from the Children's Oncology Group standard of care or patients can be enrolled on a Children's Oncology Group treatment study.
•5. is within first four courses of chemotherapy treatment

Exclusion Criteria

•Patients will be excluded from the current study if:
•1. G-CSF was added to their oncology treatment protocol due to previous complications but for whom G-CSF was not part of their original treatment protocol.
•2. are being treated for relapsed disease
•3. has clinical evidence of bone marrow involvement

Related studies

Breath Analysis for the Detection of Invasive Fungal Infections

NCT06537726 · Leukemia, Leukemia, Myeloid, and more

Danish Elder Lymphoma Patient Hematopoietic Investigation

NCT05245487 · Lymphoma, Chemotherapy-induced Neutropenia, and more

Not Yet RecruitingNA

CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors

NCT07423728 · Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization

Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF

NCT04998279 · Recurrent Implantation Failure, Granulocyte Colony-Stimulating Factor, and more

COMPLETEDPhase 2

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

NCT04345900 · Chemotherapy-induced Neutropenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 13, 2020Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment150

Start dateFeb 2019

Last updatedMar 13, 2020

Condition

Granulocyte Colony-Stimulating Factor Chemotherapy-induced Neutropenia Chemotherapy-Induced Febrile Neutropenia Pediatric Cancer

Locations shown

Univeristy of Mississippi Medical Center

Jackson, Mississippi

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions